NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 5.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,315 shares of the medical research company’s stock after selling 905 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in NeoGenomics were worth $212,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in NEO. Vanguard Group Inc. raised its holdings in shares of NeoGenomics by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 14,211,019 shares of the medical research company’s stock valued at $223,397,000 after purchasing an additional 41,354 shares in the last quarter. First Light Asset Management LLC lifted its holdings in NeoGenomics by 29.6% during the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock worth $63,535,000 after buying an additional 897,843 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after acquiring an additional 217,687 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of NeoGenomics by 5.4% in the 2nd quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after acquiring an additional 167,145 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of NeoGenomics by 77.8% during the 1st quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock worth $16,532,000 after acquiring an additional 460,071 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Stephens reiterated an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, September 25th. Finally, Benchmark reiterated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Stock Down 1.0 %

Shares of NASDAQ:NEO opened at $14.50 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The stock has a market cap of $1.85 billion, a P/E ratio of -21.97 and a beta of 1.19. NeoGenomics, Inc. has a 1-year low of $11.03 and a 1-year high of $21.22. The firm has a fifty day moving average price of $16.06 and a 200 day moving average price of $14.92.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million for the quarter, compared to the consensus estimate of $161.82 million. During the same period last year, the business posted ($0.09) EPS. The company’s revenue was up 12.0% on a year-over-year basis. Sell-side analysts predict that NeoGenomics, Inc. will post -0.22 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.